The effect of Lu-177-EDTMP-Sm-153 complex on bone pain palliation

Metastatic bone pain palliation using 177Lu/153Sm-EDTMP cocktail: a clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180203038601N1

Enrollment

Registered

2018-04-08

Start date

2015-11-22

Completion date

Unknown

Last updated

2018-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain caused by bone metastases. Other specified disorders of bone

Interventions

The 177Lu /153Sm-EDTMP cocktail is prepared from the Iran Atomic Energy Organization and 0.5 mCi/ kg of each radioactive substance is injected for the patients with bone metastases who fill out inform

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cancerous patients with metastatic lesions in bone and with a positive bone scan coincident with pain location, maximally one month before treatment Suitable CBC at least one week before treatment Normal liver and kidney function

Exclusion criteria

Exclusion criteria: Inappropriate function of liver or kidney

Design outcomes

Primary

Measure	Time frame
Pain caused by bone metastases. Timepoint: Every week for at least 12 weeks. Method of measurement: Completing the pain score form.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehr Sadat Alavi

Shiraz University of Medical Sciences

alavimh@sums.ac.ir+98 71 3612 5730

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026